Cumulus Neuroscience Digital Task Matches or Exceeds Alzheimer's Trial Benchmarks
Cumulus Neuroscience presented data at an Alzheimer's conference showing its two-minute digital Symbol Swap task. The task measures cognitive function and demonstrated accuracy matching or exceeding traditional clinical assessments for Alzheimer's trial pre-enrichment. The company released findings on the task's effectiveness in identifying disease progression and its potential to streamline recruitment for clinical studies.
London, July 15, 2026 – Cumulus Neuroscience presented new data on its NeuLogiq® Platform's two-minute digital Symbol Swap task at the Alzheimer's Association International Conference 2026.
Across three independent studies, the two-minute, tablet-based Symbol Swap task provided clinically meaningful discrimination between control, mild cognitive impairment (MCI), and Alzheimer's dementia groups. The task also detected biomarker-defined pathology, including in cognitively normal individuals, with accuracy matching or exceeding ADAS-Cog, MoCA, and MMSE benchmarks.
Cumulus Neuroscience stated that the Symbol Swap task significantly reduces the burden on participants and research sites in clinical trials for Alzheimer's disease. The data suggests it could serve as an effective first-line screening filter, preceding more invasive or costly biomarker tests. The automatically scored, digitally administered task scales well for large, multi-site trials, enabling both in-clinic and at-home assessments.
"It is striking that a two-minute, patient-friendly task can match or beat assessments that take a trained clinician 10 to 45 minutes to administer," said Brian Murphy, Cumulus Co-Founder and CSO. "This data confirms that Symbol Swap may be a powerful first-line filter, preceding plasma biomarkers or feeding composite digital endpoints." Additional posters also presented multi-domain digital endpoints from the NeuLogiq Platform in decentralized Alzheimer's trials.